Key result
XV454 is a potent, selective platelet GPIIb/IIIa antagonist with high affinity and a slow dissociation rate, providing long-lasting antiplatelet efficacy in non-human primates.
Why the study?
Does XV454 inhibit platelet aggregation and demonstrate favorable binding kinetics compared to c7E3 in preclinical models?
Does XV454 inhibit platelet aggregation and demonstrate favorable binding kinetics compared to c7E3 in preclinical models?
XV454 is a potent, highly selective platelet GPIIb/IIIa antagonist with high affinity and slow dissociation, providing long-lasting antiplatelet efficacy in preclinical models.
Answers are grounded in this paper and cite their sources.
XV454's primate data support further preclinical development; leaves open clinical translation and comparison to c7E3.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Mousa et al. (1998) studied this question. XV454 vs. c7E3 was evaluated on Platelet aggregation inhibition and binding affinity. XV454 is a potent, selective platelet GPIIb/IIIa antagonist with high affinity and a slow dissociation rate, providing long-lasting antiplatelet efficacy in non-human primates.
Synapse has enriched 10 related papers. Consider them for comparative context: